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Cerebral reserve is decreased in elderly patients
with carotid stenosis
Rabih A. Chaer, MD, James Shen, BS, Atul Rao, MD, Jae S. Cho, MD, Ghassan Abu Hamad, MD, and
Michel S. Makaroun, MD, Pittsburgh, Pa
Objectives: Octogenarians and even patients over 70 years old have unexplained poor outcomes with carotid angioplasty
and stenting (CAS). We sought to evaluate whether older patients may have compromised intracranial collaterals and
cerebral reserve and be intolerant to otherwise clinically silent emboli generated during CAS.
Methods: One thousand twenty-four cerebral blood flow (CBF) studies performed between 1991 and 2001 with stable
xenon computed tomography scans (Xe/CT) were reviewed. CBF was measured before and after 1 gm intravenous
acetazolamide (ACZ), a cerebral vasodilator. The normal response to ACZ is an increase in CBF. In areas of significant
compromise of cerebral reserve (CR), CBF drops, representing a “steal” phenomenon. CBF changes were categorized as
normal or abnormal and correlated with age, gender, cerebral symptoms, and with intracranial, carotid, or vertebral
artery disease. Logistic regression was used to determine the effect of age on CR in the entire group and a subgroup of 179
patients with significant carotid stenosis of >50%.
Results: Nine hundred sixteen studies were suitable for analysis. Carotid occlusion was predictive of decreased reserve
(OR, 3.9; P  .03) regardless of age. There was also a trend toward lower reserve with severe carotid stenosis >70%
(OR, 3) and in women (OR, 1.8; P .08). Age>70 had no effect on reserve in the overall heterogeneous population with
and without carotid disease and neither did a history of stroke, carotid, or intracranial stenosis. However, in 179 patients
with significant carotid stenosis, age >70 was predictive of poor reserve (OR, 2.7; P  .03) and so was the presence of
peripheral vascular disease (OR, 3.7; P  .03). A trend toward decreased reserve was also seen in women (OR, 2.3;
P  .08).
Conclusions: Age >70 is associated with poor cerebral reserve in patients with significant carotid stenosis as measured by
CBF response to an ACZ challenge. Thus, patients >70 may be more sensitive to minor cerebral emboli, which may be
one factor explaining their higher risk of stroke during CAS. (J Vasc Surg 2010;52:569-75.)Carotid angioplasty and stenting (CAS) is currently
accepted as a less invasive alternative to carotid endarterec-
tomy (CEA). While initially anticipated to be a replacement
for CEA for most indications, high-risk criteria for CAS
have emerged cautioning against the universal application
of the technique.1,2 Older patients, most notably octoge-
narians, represent a subset at especially high risk for com-
plications with CAS. Several studies have demonstrated
increased rates of stroke and death among elderly patients
with carotid stenosis treated with CAS.3-5 Although many
studies focused on patients in their 80s, evidence suggests
an increased risk even with advanced age over 70.6,7
The etiology of increased adverse event risk associated
with CAS in the elderly remains incompletely understood.
It has been suggested that hostile vascular anatomy and
lesion characteristics that increase the technical complexity
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doi:10.1016/j.jvs.2010.04.021of CAS are more prevalent in the elderly and may account
for this finding.8-10 Although many lesion characteristics
that result in an increased risk of stroke are sometimes
independent of advanced age,11 adverse anatomy remains
more prevalent with increasing patient age.
The effect of cerebral reserve on outcomes of carotid
interventions for occlusive disease remains poorly defined,
especially in older patients who might have intracranial
occlusive disease as well as various degrees of brain atrophy
that may limit their tolerance for minor emboli. CAS is well
known to result in frequent subclinical microemboli de-
tected as filling defects on early diffusion MRI.12,13 It is
plausible that compromised cerebral reserve in the elderly
may unmask the subclinical nature of these events, account-
ing for the increased rate of clinically significant symptom-
atic stroke.
Although compromised cerebral blood flow is a known
predictor of stroke in patients with carotid artery occlusive
disease,14-16 the effect of age on cerebral reserve in this
setting remains poorly defined, and may explain the poor
outcomes associated with CAS in this patient population.
Stable xenon computed tomography (Xe/CT) CBF map-
ping had been readily available in the US and continues to
be used widely overseas, offering a valuable technique for
measuring CBF. It allows CR to be easily be assessed by the
response to a cerebral vasodilator challenge, acetazolamide
(ACZ). The purpose of this study was to evaluate whether
older patients may have compromised intracranial collater-
als and CR as measured by stable Xe/CT and thus are
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that are generated during CAS.
METHODS
The records of all patients evaluated with a Xe/CT
CBF mapping before and after ACZ administration be-
tween 1991 and 2001 at the University of Pittsburgh
Medical Center were retrospectively reviewed following
approval by the Institutional Review Board. Stable xenon
ceased to be readily available for clinical use in 2001 as
mandated by the FDA, therefore limiting the study period.
Patients with inadequate follow-up examination or techni-
cally poor studies secondary to motion artifact were ex-
cluded from this review: 108 studies were inadequate and
were excluded. Out of 1024 patients identified, only 916
had studies that were deemed suitable for analysis. The
entire cohort was analyzed initially and then stratified by
the presence or absence of carotid stenosis when carotid
testing was available. Information on the status of the
carotid vasculature was available for the review in 780
patients (85%) and was based on duplex imaging, com-
puted tomography, or magnetic resonance angiography.
Patients were stratified by the presence or absence of ca-
rotid stenosis, defined as the presence of a 50% internal
carotid stenosis. Two categories of carotid stenosis were
therefore used in the analysis model, and patients with
carotid occlusion were separately analyzed.
Normal mixed cortical CBF (averaged gray and white
matter) is approximately 50 to 55 mL/100 gm brain
tissue/min. However, this baseline value is variable and can
be decreased as a result of either decreased supply or
demand. Because compromised cerebral hemodynamics
are associated with maximum vasodilatation, CBF response
to a vasodilatory challenge should provide a better assess-
ment of vascular reserves or reactivity. Acetazolamide
(ACZ; Diamox) induces maximal cerebral vasodilatation
caused by tissue acidosis. The normal response is a signifi-
cant (20%-40%) increase in CBF in all vascular territories.
CBF was measured with the stable Xe/CT CBF technique
described by Gur et al.17 Stable xenon gas is radiodense,
lipid-soluble, and diffuses rapidly and freely across the
blood-brain barrier. Xe-enhanced CT scan allows the iden-
tification of structural lesions that may be invisible on
conventional CT imaging and MRI.18 Stable xenon gas is
used as a contrast agent by inhaling a mixture of xenon
(26%-33%) and oxygen after obtaining baseline CT images.
A second set of images is then obtained where the distribu-
tion of xenon shows regional blood flow. With the use of
equations based on the Fick principle, CBF was calculated
and reported for each voxel (1 1 10 mm) based on the
rate of change of CT density and the concurrent arterial
curve obtained directly from the end tidal measurement of
xenon concentration by thermoconductivity. This tech-
nique had been standardized for routine clinical applica-
tions, and hardware and software packages for performing
Xe/CT CBF mapping were utilized.17 CBF is calculated
and reported for any anatomic location in the brain. Base-
line flows are initially obtained, and the study is thenrepeated after a 20-minute washout period following the
intravenous administration of 1 gm ACZ. ACZ results in
cerebral vasodilatation and unmasks any areas of dimin-
ished reserves. Whereas the normal response to ACZ is a
20% to 40% augmentation of flow in all vascular territories,
areas with poor perfusion and limited reserves show a
decrease in CBF akin to cardiac stress testing with nuclear
imaging. Although CBF may change little in areas of basal
vasodilatation with moderate collateral compromise, it may
actually drop in territories with severe compromise of col-
laterals representing a “steal” phenomenon (Fig).
Patients were stratified into two groups of vascular
reactivity depending on the CBF response to ACZ. Patients
with a relatively normal response had no more than a 5%
decrease in any vascular territory after ACZ challenge.
Patients with an abnormal response had a decrease of more
than 5% in at least one vascular territory after vasodilatory
challenge. The choice of a 5% decrease in CBF as a cutoff
value was used to clearly identify a physiologically abnormal
group and is based on previous work analyzing cerebral
reserve in patients with symptomatic carotid stenosis.17
Although the use of a 5% decrease as a breakpoint is
somewhat arbitrary, it is based on the recognition that
failure to augment after vasodilatory challenge is an abnor-
mal response. Allowing for a 5% variance in CBF measure-
ments makes the group with 5% decrease a clearly physi-
Fig. Xenon/CT CBF study. A and C represent regular baseline
computed tomography images for comparison and anatomic cor-
relation. Blood flow maps prior to and after the administration of
acetazolamide (ACZ) are shown in B and D, respectively. After
ACZ, cerebral blood flow (CBF) is reduced primarily in the right
middle cerebral artery territory. Color key shows CBF in cc/100
gm/min. Numbers in B and D indicate mean CBF values in the
relevant regions of interest (circled areas). (Reproduced with per-
mission from Yonas et al. J Neurosurg 1993;79:483-9.)ologically abnormal group. The most hemodynamically
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determine group classification.
Statistical analyses were performed with the SAS statis-
tical package (version 9.2; SAS Institute Inc., Cary, NC).
Univariate and multivariate analyses were performed. Ad-
justment for the effect of medical comorbidities, gender,
medications, and peripheral vascular disease was included.
A multinominal logit model to estimate the effect of age
and other variables on various levels of reserve levels (nor-
mal vs abnormal) was used.
A subgroup of patients with carotid stenosis was stud-
ied using a logistic regression to estimate the effect of age
on the likelihood of having an abnormal test. A value of P
.05 was considered significant, all reported P values were
2-sided, and all odds ratios (OR) are reported with a 95%
confidence interval.
RESULTS
Indications for Xe/CT and cerebral reserve. Cere-
bral blood flow imaging with Xe/CT was performed in a
large heterogeneous patient population with and without
cerebrovascular occlusive disease. The demographic char-
acteristics and comorbidities are detailed in Table I. Infor-
mation on medical comorbidities and medications was
available on all patients and was determined based on the
patient record at the time of the index hospitalization. The
diagnosis of peripheral vascular disease was assigned to all
patients with a history of claudication, critical limb isch-
emia, or previous peripheral vascular surgery. Renal failure
included all patients on dialysis, and congestive heart failure
was based on clinical diagnoses and echocardiographic
findings. Race was predominantly white, reflecting geo-
graphic location, and genders appeared to be equally rep-
resented.
Surprisingly, while the majority of patients carried the
diagnosis of coronary or cerebrovascular disease, most were
not on antiplatelet or statin therapy. This is certainly not in
accordance with current standards, yet it is not clear
whether these patients had been under active medical care
Table I. Overall patient characteristics
Characteristic
Overall population
N  916
Frequency (n) or mean  SD
Mean age (years) 61.4  14
Race (white) 91% (832)
Gender (female) 44% (404)
Diabetes mellitus 24% (222)
Renal failure 8% (73)
Peripheral vascular disease 21% (189)
Stroke 11% (104)
Statin therapy 7% (60)
Antiplatelet therapy 22% (198)
Coronary artery disease 85% (775)
Congestive heart failure 19% (170)
History of myocardial infarction 23% (207)prior to the index admission.The most common indications for CR evaluation in-
cluded stroke of any cause and carotid stenosis (Table II).
However, nearly 27% of tests were obtained for a variety of
different reasons with a wide age group range, especially
when evaluating younger trauma patients or patients with
cerebral aneurysm rupture prior to possible neurosurgical
intervention.
Several age ranges were examined in a logistic regres-
sion model to determine the effect on CR:70 years, 70 to
80 years, and 80 years. Age 70 had no effect on CR in
the overall patient population (OR, 1.32 [0.85-2.05];
P  .21), even after adjusting for the presence of carotid
stenosis (OR, 1.02 [075-1.39]; P  .90).
Carotid occlusion was the only variable clearly associ-
ated with decreased CR (OR, 3.9 [1.1-9.9]; P .03) in this
heterogeneous patient population, regardless of age. There
was also a trend for diminished CR with severe carotid
stenosis 70% (OR, 3 [0.89-10.1]; P  .08) and female
gender (OR, 1.8 [0.96-2]; P  .08), although this did not
quite reach statistical significance.
Other factors evaluated in the model included gender
and race, as well as effect of pharmacotherapy with anti-
platelet agents, lipid-lowering agents, beta-blockers, and
warfarin anticoagulation, all of which did not seem to have
an effect on CR.
Moreover, advanced age70 did not appear to portray
a higher incidence of cerebrovascular occlusive disease be-
cause it was not predictive of the presence of carotid,
vertebral, or intracranial occlusive disease and had no effect
on CR in this mixed population with and without carotid
disease. In addition, a previous history of stroke, carotid,
vertebral, or intracranial stenosis also had no significant
effect on reserve in this patient population. The frequency
of abnormal cerebral reserve in the overall patient popula-
tion is detailed by patient characteristic and comorbidity in
Table III.
There were 618 patients 70 years old in the overall
series, 95 of whom had a confirmed50% carotid stenosis.
The overall prevalence of abnormal CR in patients 70
years of age was 45%. In the subset of young patients 70
years with carotid stenosis, 42% had diminished CR. By
logistic regression analysis, the presence of carotid stenosis
was not predictive of abnormal CR (P  NS). Similarly,
Table II. Indications for Xe/CT in the overall
population (N  916)
Indication N (%)
Stroke 47% (426)
Carotid stenosis 40% (363)
Cerebral aneurysm rupture 16% (147)
Vertebrobasilar insufficiency 3% (28)
Intracranial occlusive disease 1% (10)
Trauma/intracranial bleed 1% (11)
Central nervous system tumor 1% (3)
Other 5% (46)gender, renal failure, peripheral vascular disease, coronary
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predictors of diminished CR in this patient population (P
NS). A previous history of myocardial infarction (MI) in
patients 70 years was predictive of diminished reserve
(OR, 1.92 [1.19-3.1]; P .01), regardless of the presence
of carotid stenosis.
CR in patients with carotid stenosis. Patients with
carotid stenosis were selected from the overall patient pop-
ulation tested with a Xe/CT for evaluation of CR. Patients
were then categorized in two groups depending on the
degree of carotid stenosis: less or greater/equal to 50% as
determined by duplex ultrasound. While there were 363
patients who carried the diagnosis of carotid stenosis, only
179 were included in the analysis to reflect the presence of
at least a 50% stenosis or greater. A moderate stenosis
indicated a 50% to 69% narrowing, and a severe stenosis
indicated a 70% narrowing on duplex ultrasound.
The characteristics of patients diagnosed with 50%
carotid stenosis by duplex ultrasound (N  179) are de-
tailed in Table IV. The demographics of this subgroup of
patients and their comorbidities were otherwise equivalent
to the overall patient population. These patients were
equally undertreated with antiplatelet and statin therapy.
In this subgroup of patients, old age 70 was strongly
predictive of poor CR (OR, 2.7 [1.1-6.5]; P  .03). This
association remained significant, regardless of the severity
of stenosis. The presence of peripheral vascular disease
(PVD) was also associated with poor CR (OR, 3.7 [1.1-
12.7]; P .03). A trend toward poor CRwas also observed
in women (OR, 2.3 [0.9-5.7]; P  .08) but did not quite
reach statistical significance. Symptomatic status, on the
other hand, was not an independent predictor of poor CR
Table III. Frequency of abnormal cerebral blood flow in
patients by physical characteristic
Characteristic
Overall population
N  916
Carotid stenosis
population
N  179
Frequency (n) Frequency (n)
Age 70 years or older 47% (139/298) 55% (46/84)
Age less than 70 years 45% (277/618) 42% (40/95)
White 46% (380/832) 47% (80/170)
Non-white 43% (36/84) 67% (6/9)
Female 47% (188/404) 51% (36/71)
Male 45% (228/512) 46% (50/108)
Diabetes 45% (100/222) 47% (28/60)
Renal failure 47% (34/73) 47% (9/19)
Peripheral vascular
disease 47% (89/189) 57% (26/46)
Stroke 47% (49/104) 46% (10/22)
Statin therapy 45% (27/60) 35% (7/20)
Antiplatelet therapy 45% (90/198) 47% (21/45)
Coronary artery disease 47% (363/775) 49% (79/160)
Congestive heart failure 46% (78/170) 52% (30/58)
History of myocardial
infarction 53% (109/207) 49% (30/61)
Carotid stenosis 48% (86/179) –in this patient population (OR, 0.27 [0.05-1.3]; P  .1).Moreover, previous stroke, MI, congestive heart failure
(CHF), diabetes, intracranial or vertebral stenosis, and race
showed no association with poor CR. Similarly, antiplatelet
therapy, anticoagulation with coumadin, and lipid-lowering
statin therapy had no effect on CR either. The frequency of
abnormal cerebral reserve in subjects with carotid stenosis is
detailed by patient characteristic and comorbidity inTable III.
DISCUSSION
Only recently has attention focused on identification of
patients who may be at high risk for complications during
and after CAS, including the presence of specific vascular
anatomic characteristics, symptomatic patients, and octo-
genarians.1,2 Although agreement is far from universal, the
evidence is nearly overwhelming that advanced age is asso-
ciated with increased adverse events. Several studies have
demonstrated increased rates of stroke and death among
octogenarians. The Carotid Revascularization Endarterec-
tomy versus Stenting Trial (CREST) lead-in phase reported
a 30-day stroke and death rate of 12.1% for octogenarians
compared with 3.2% among nonoctogenarians (P 
.0001), leading to caution in enrollment of patients 80
years of age and older in the study.3 Similarly, results from
Stanziale and associates indicated that CAS in octogenari-
ans was associated with a statistically significantly higher
rate of adverse events at 30 days and at 1-year follow up.4
More recently, a subgroup analysis of the Stent-Supported
Percutaneous Angioplasty of the Carotid Artery versus
Endarterectomy (SPACE) trial also found that the rate of
complications was significantly associated with age in the
CAS group; patients in the CEA group had homogenous
event rates across all age groups.6 The etiology of increased
adverse event risk for CAS in the elderly remains incom-
pletely understood. It has been suggested that adverse
vascular anatomy and lesion characteristics that have the
potential to increase the technical complexity of CAS may
account for this finding, since recent studies have suggested
that some of these complex anatomic features seem to be
Table IV. Characteristics of patients with carotid
stenosis
Characteristic
Carotid stenosis population
N  179
Frequency (n) or mean  SD
Mean age (years) 67.5  12
Race (white) 95% (170)
Sex (female) 40% (71)
Diabetes mellitus 34% (60)
Renal failure 11% (19)
Peripheral vascular disease 26% (46)
Stroke 12% (22)
Statin therapy 11% (20)
Antiplatelet therapy 25% (45)
Coronary artery disease 89% (160)
Congestive heart failure 32% (58)
History of myocardial infarction 34% (61)more prevalent among older patients.8,9 Lin and coworkers
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innominate artery stenosis, and tortuosity of the common
and internal carotid arteries were significantly more severe
in patients greater than 80 years old.8 Likewise, in addition
to the features mentioned earlier, others have also found
unfavorable arch elongation, severe lesion stenosis greater
than 85%, and plaque ulceration to be significantly more
common among patients age 80 years and older.10
Variables that have been associated with increased
risk of adverse events include abnormal arch anatomy,19
vessel tortuosity,20 long stenotic lesions (15 mm),11
involvement of the internal carotid ostium, and plaque
echolucency.21 However, it is important to also note that,
although these anatomic and lesion characteristics are
thought to be more common in the elderly population,
younger patients may also have similar unfavorable risk
factors since long stenoses and ostial involvement were
associated with increased risk of stroke independent of
octogenarian status.11
Embolization during CAS is not uncommon but not
always clinically significant.12,13 It can occur at different
stages of the procedure, including aortic arch navigation,
during positioning, and even after deployment of cerebral
protection devices.22-24 The current generation of com-
mercially available filters have pore sizes of 100 to 150 m.
Meanwhile, high-volume microemboli60 m have been
demonstrated in experimental models at all stages of the
procedure, including the initial wire passage. In addition,
routine use of cerebral protection devices has been associ-
ated with a significant number of diffusion-weighted mag-
netic resonance imaging defects, especially in a group of
octogenarians.12 This may therefore affect an already di-
minished cerebral reserve in a group of patients with com-
promised collateral circulation.
Cerebral reserve has not been clearly correlated with
the outcomes of CAS, and the effect of age on CR is not
well defined. Several brain perfusion imaging modalities
have been proposed for the quantification of CR. These
techniques give similar information about brain perfusion
in the form of hemodynamic parameters such as cerebral
blood flow or volume. All of them are used to characterize
the same types of pathological conditions. However, each
technique has its own advantages and drawbacks.25
Xe/CT with an ACZ challenge is a reproducible quan-
titative technique that can be more easily used in the
current clinical settings. The main present limitation of this
imaging modality is its lack of availability. Although medi-
cal-grade xenon is available and distributed worldwide, it is
not currently approved by the FDA. In 2001, the FDA
withdrew xenon’s status as a “grandfathered” contrast
agent and required studies for reapproval. The technology
is only available at this time under Investigational New
Drug status.
Cerebrovascular reserve assessed by examining the
quantitative response of flow by Xe/CT in patients with
carotid occlusive disease has provided a means for identify-
ing high-risk subgroups.14,15 Patients with symptomatic
carotid disease who have significantly compromised CBFvasoreactivity even despite normal baseline CBF appear to
have a substantial risk for stroke.
The results of the current study using Xe/CT suggest
that CR does not diminish with age when evaluated in a
heterogeneous patient population, even after controlling
for carotid and intracranial cerebrovascular disease. How-
ever, the effect of intracranial occlusive disease on CR
cannot be adequately determined from this mixed popula-
tion series since only a minority of patients was diagnosed
with intracranial disease.
On the other hand, old age70 in patients with50%
carotid stenosis had a significant association with abnormal
cerebral reserve when compared with younger patients and
was not affected by the presence of stroke or TIA. Dimin-
ished CR is a marker of compromised cerebral collateral
circulation, and these patients may therefore be intolerant
to minor otherwise silent emboli generated during the
different stages of CAS. These findings suggest that elderly
patients with carotid stenosis, regardless of symptom status,
may be at a higher risk of stroke with CAS because of
diminished baseline reserve. It is therefore possible that the
combination of adverse lesion pathology and arch anatomy,
as well as poor reserve, places the elderly at a particularly
high risk of neurologic adverse events during CAS.
Statin and antiplatelet therapy had no significant effect
on reserve in this series. However, the proportion of pa-
tients on thesemedications was relatively small, especially in
view of the fact that the majority of patients carried the
diagnosis of coronary or cerebrovascular disease and would
be on both classes of drugs by current standards. The lack of
a protective effect on reserve should therefore be inter-
preted with caution.
There are multiple limitations to this study. This is an
older dataset limited by the fact that Xe/CT was not
routinely available after 2001. The retrospective nature of
this analysis also limited the possibility of any adequate
follow-up. Furthermore, the subset of patients with carotid
stenosis represented only a fraction of all the patients eval-
uated by a Xe/CT, therefore limiting the applicability of
these results to a broader patient base. Nevertheless, mea-
suring cerebral reserve in patients being considered for
treatment of carotid stenosis is attractive, and may give an
insight on the expected functional and cognitive outcomes
anticipated with revascularization. Evaluation of reserve
could also prove to be beneficial in treatment algorithms for
carotid occlusive disease and may guide the choice of the
optimal revascularization technique for each individual pa-
tient.
CONCLUSIONS
Age 70 is associated with poor cerebral reserve in
patients with significant carotid stenosis as measured by
CBF response to an ACZ challenge. Elderly patients could
therefore be at a higher risk of stroke during CAS due to
compromised collateral channels and should be offered
alternative treatment modalities. However, a larger-scale
evaluation of cerebral reserve using currently available im-
aging techniques in patients with carotid occlusive disease is
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Dr Philip Goodney (Lebanon, NH). I think this is an elegant
investigation into the pathophysiology underlying higher stroke rates
following carotid stenting in patients of older age groups. I think these
findings are intriguing, and I have several questions toward this end.
First, I have a technical question about the imaging results.
Was the decrease in cerebral reserve always ipsilateral to the carotid
stenosis or occlusion? How often did it tend to cross over to the
other hemisphere? And did that differ by stenosis or occlusion?
My second question focuses on your hypothesis that carotid
stenosis may cause a decrease in cerebral reserve, as detected by
your imaging methods. One would anticipate, however, that pa-didn’t find that. I wonder if that’s a sample size issue or if you had
some insight into that.
My third question pertains to the rates of statin and antiplate-
let therapy in this population in your study. As you pointed out,
patients with coronary disease and even those patients with symp-
tomatic carotid disease were on fairly low rates of statin and
antiplatelet therapy. I know this is a population that’s drawn over a
10-year period, so I wonder if you found that those rates increased
over time.
And just lastly, you mentioned that barriers exist to the use of
this technology in the US. How are you and your colleagues
dealing with these barriers in Pittsburgh?
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Volume 52, Number 3 Chaer et al 575Dr Rabih Chaer (Pittsburgh, Pa). The laterality of abnormal
blood flow scans was equally distributed as compared with the site
of the stenosis. Laterality of an abnormal xenon scan may not be
relevant in this situation since emboli that are generated during
carotid angioplasty and stenting can be bilateral as they can origi-
nate from the arch.
Regarding the number of patients that were treated with
statins or antiplatelets, this is clearly one of the limitations of a
retrospective analysis. Perhaps this wasn’t common therapy back
then, but it certainly does not reflect current practice.
Regarding the availability of the xenon study, xenon’s privi-
leged status as a contrast agent in the United States was revoked by
the FDA in 2001. It is currently readily available overseas but not
in the US, although reapproval may be expected in the future.
Regarding your question on intracranial stenoses, this was
specifically analyzed because one would expect, as you mentioned,
that it will have a significant effect on reserve. I do suspect that the
lack of significant association between reserve and intracranial
stenosis is related to the small sample size of patients with intracra-
nial stenosis, as pointed out.
Dr James Black (Baltimore, Md). I’ve been thinking about
this subject a lot lately because I had a patient just a couple weeks
ago who had a watershed stroke after what I thought was a pretty
uneventful carotid procedure. As a matter of fact, over the past 5
years, three of the patients who have had strokes in my hands with
carotid surgery, two of the three were called watershed by subse-
quent imaging. The imaging that showed that was an MRI with
perfusion and diffusion-weighted images. And could you just
enlighten us as to what the overlap could be, with the available
study we have, to determine watershed vs embolic, that is MRI,
and what this technology is, so we could sort of compare apples
and apples?
Then the other question, of course, is, do you have any
long-term data about the patients who had poor cerebral reserve in
terms of their overall survival, or could that be obtainable in the set
that you have?
Dr Chaer. There have been a few studies comparing diffusion
MRI with xenon CT. There are multiple modalities that one could
use for the physiologic imaging of the brain. Xenon CT scanning
seems to always pan out as the most accurate and preferredmodality; although diffusionMRI comes close, but it is not equally
accurate.
Xenon CT remains frequently utilized outside the US as the
pre- and postoperative imaging modality of choice in dedicated
centers performing intracranial bypass surgery. I don’t have long-
term follow-up on those patients. I do suspect that perhaps many
of them are deceased, since the data collection stopped in 2001.
Dr Wei Zhou (Palo Alto, Calif). A total of 47% of your
patient cohort had a history of stroke. Did any of the patients
undergo revascularization procedures? If so, was there any im-
provement in cerebral blood flow on the xenon CT?
Dr Chaer. The etiology of stroke in this series was multifac-
torial and included embolic sources as well as aneurysm rupture
and bleeding. Those patients who had revascularization proce-
dures for severe carotid stenosis did not routinely get a xenon serial
blood flow study as a follow-up.
Dr Vance Smith (Muskegon, Mich). A number of years ago,
there were several papers on CO2 reactivity stress testing with
transcranial doppler that showed a correlation with hemodynami-
cally significant stenosis in the cervical carotid and also a correlation
with stroke in the untreated patients. And particularly in patients
who had an occlusion, ipsilateral or contralateral, there was an
increased risk of stroke if they had decreased cerebral vascular
reserve on TCD CO2 reactivity stress testing, which is pretty easy
to do, just having them rebreathe in a gallon ziplock baggie. It
appeared beneficial to anticoagulate some occlusion patients with
reduced cerebrovascular reserve. I wonder if TCD CO2 reactivity
stress testing was something of interest to you or if you looked into
it. I found it useful in my practice evaluating the significance of
carotid stenosis, and I think it’s been useful selecting some patients
with carotid occlusions having a higher stroke rate and benefiting
from anticoagulation.
Dr Chaer. A recent study has compared xenon CT to TCD
imaging. Xenon CT imaging provided better brain physiologic
imaging. You do raise a significant question, however, as we had
demonstrated in a previous study with xenon CT that the loss of
cerebral reactivity in symptomatic patients with carotid occlusion
or severe 70% carotid stenosis was predictive of cerebral infarc-
tion.
